about
Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions.Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings.Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.Bipolar II and the bipolar spectrum.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Valproate in bipolar disorder: 2000 onwards.Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease researchThe wnt pathway in mood disordersSafety and tolerability of mood-stabilising anticonvulsants in the elderly.Spectrum of effectiveness of valproate in neuropsychiatry.Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats.Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.Sex differences in rates of obesity in bipolar disorder: postulated mechanisms.Management of comorbid bipolar disorder and substance use disorders.Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.Functional hallucinations in schizophrenia responding to adjunctive sodium valproate.The effects of vitamin B6 on lens antioxidant system in valproic acid-administered rats.Antifibrogenic role of valproic acid in streptozotocin induced diabetic rat penis.Anticonvulsants in bipolar disorder
P2860
Q30724630-C0F07E2B-E343-4B3D-ACE1-0CC9D48B29CFQ30980756-001FA57C-21C0-4162-98CA-54DEC888C2CAQ33518859-49DD588A-0459-45B3-8B72-EB0981CE7071Q34497641-EDA89571-D2A3-4672-B539-EB7F1F29F40FQ35862776-58B76A4C-EC35-4280-8FE2-F44FA768FD53Q36099536-5F35610B-E993-4521-80E8-AD1DC680BC30Q36129673-A3ED2B9C-7E63-4485-BC44-67E4C58CC98DQ36310513-D6E2B634-CB71-4A00-9E04-A735D9922E4BQ36446899-92E89167-578D-4152-B978-0EE2A40BBDC2Q36691749-CEEF2D8F-A84E-4221-83E0-85B533949ED3Q36930683-7B98D3C2-FEE3-47E8-9EA1-796138538788Q37171035-EAB0E0FD-0C70-4E53-9DD1-8490857F60B9Q38182163-E3934062-7F20-4372-A506-5B1918346D73Q39181932-D4A7928F-A2B2-4D65-A667-F49FA292C16BQ40039773-F5C2A5FC-B852-4114-839F-30E050CA51F7Q42006502-C62E8AA7-48E1-404F-9B0C-087FB89CCF92Q47963313-91530F0D-A700-475E-B0C2-9F2950BD70DEQ53378646-6B9CF3E6-426B-42A9-926E-15676FFF01C5Q56637792-E8991C49-D745-47C2-B37C-C3D8105C4C50
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Valproate.
@ast
Valproate.
@en
type
label
Valproate.
@ast
Valproate.
@en
prefLabel
Valproate.
@ast
Valproate.
@en
P2860
P1433
P1476
Valproate.
@en
P2093
Charles L Bowden
P2860
P304
P356
10.1034/J.1399-5618.2003.00031.X
P577
2003-06-01T00:00:00Z